

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-C

Report by Issuer of Securities Quoted on NASDAQ  
Inter-Dealer Quotation System Filed Pursuant to  
Section 13 or 15(d) of the Securities Exchange Act  
of 1934 and Rules 13a-17 and 15d-17 Thereunder

ImmunoGen, Inc.

-----  
(Exact name of Issuer as Specified in Charter)

128 Sidney Street, Cambridge, Massachusetts 02139

-----  
(Address of Principal Executive Offices)

(617) 661-9312

-----  
(Issuer's Telephone Number, Including Area Code)

I. CHANGE IN NUMBER OF SHARES OUTSTANDING

Indicate any change (increase or decrease) of five percent or more in the  
number of shares outstanding:

1. Title of security   ImmunoGen, Inc. Common Stock  
-----
2. Number of shares outstanding before the change 12,586,606  
-----
3. Number of shares outstanding after the change 13,656,884  
-----
4. Effective date of change   November 6, 1995  
-----
5. Method of change:

Specify method (such as merger, acquisition, exchange, distribution, stock  
split, reverse split, acquisition of stock for treasury, etc.)

Conversion of Subordinated Convertible Debentures  
-----

Give a brief description of transaction   Conversion of Subordinated  
-----  
Convertible Debentures issued in previous Regulation S transaction.  
-----

II. CHANGE IN NAME OF ISSUER

1. Name prior to change   -----
2. Name after change   -----
3. Effective date of charter amendment changing name   -----
4. Date of shareholder approval of change, if required   -----

Date January 12, 1996

/S/ Frank J. Pocher, Vice Pres-  
ident and Chief Financial Officer

-----  
(Officer's Signature and Title)

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-C

Report by Issuer of Securities Quoted on NASDAQ  
Inter-Dealer Quotation System Filed Pursuant to  
Section 13 or 15(d) of the Securities Exchange Act  
of 1934 and Rules 13a-17 and 15d-17 Thereunder

ImmunoGen, Inc.

-----  
(Exact name of Issuer as Specified in Charter)

128 Sidney Street, Cambridge, Massachusetts 02139

-----  
(Address of Principal Executive Offices)

(617) 661-9312

-----  
(Issuer's Telephone Number, Including Area Code)

I. CHANGE IN NUMBER OF SHARES OUTSTANDING

Indicate any change (increase or decrease) of five percent or more in the  
number of shares outstanding:

1. Title of security ImmunoGen, Inc. Common Stock

2. Number of shares outstanding before the change 13,656,884

3. Number of shares outstanding after the change 14,347,799

4. Effective date of change November 29, 1995

5. Method of change:

Specify method (such as merger, acquisition, exchange, distribution, stock  
split, reverse split, acquisition of stock for treasury, etc.)

Conversion of Subordinated Convertible Debentures

-----  
Give a brief description of transaction Conversion of Subordinated  
Convertible Debentures issued in previous Regulation S transaction.  
-----

II. CHANGE IN NAME OF ISSUER

1. Name prior to change

2. Name after change

3. Effective date of charter amendment changing name

4. Date of shareholder approval of change, if required

Date January 12, 1996

/S/ Frank J. Pocher, Vice Pres-  
ident and Chief Financial Officer

-----  
(Officer's Signature and Title)

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-C

Report by Issuer of Securities Quoted on NASDAQ  
Inter-Dealer Quotation System Filed Pursuant to  
Section 13 or 15(d) of the Securities Exchange Act  
of 1934 and Rules 13a-17 and 15d-17 Thereunder

ImmunoGen, Inc.

-----  
(Exact name of Issuer as Specified in Charter)

128 Sidney Street, Cambridge, Massachusetts 02139

-----  
(Address of Principal Executive Offices)

(617) 661-9312

-----  
(Issuer's Telephone Number, Including Area Code)

I. CHANGE IN NUMBER OF SHARES OUTSTANDING

Indicate any change (increase or decrease) of five percent or more in the number of shares outstanding:

1. Title of security   ImmunoGen, Inc. Common Stock  
-----
2. Number of shares outstanding before the change 14,347,799  
-----
3. Number of shares outstanding after the change 15,074,226  
-----
4. Effective date of change   December 13, 1995  
-----
5. Method of change:

Specify method (such as merger, acquisition, exchange, distribution, stock split, reverse split, acquisition of stock for treasury, etc.)

Conversion of Subordinated Convertible Debentures  
-----

Give a brief description of transaction   Conversion of Subordinated  
-----  
Convertible Debentures issued in previous Regulation S transaction.  
-----

II. CHANGE IN NAME OF ISSUER

1. Name prior to change   -----
2. Name after change   -----
3. Effective date of charter amendment changing name   -----
4. Date of shareholder approval of change, if required   -----

Date January 12, 1996  
-----

/s/ Frank J. Pocher, Vice Pres-  
ident and Chief Financial Officer  
-----

(Officer's Signature and Title)